*|MC:SUBJECT|*
up-to-date with a click!
Update May 2017
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.

The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Key publications

Other

  1. Luo F, Guo Y, Ruan GY et al. Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet. Scientific reports 2017; 7:2169. http://www.ncbi.nlm.nih.gov/pubmed/?term=28526884

Add on treatments

  1. Kumagai N, Nusser JA, Inoue H et al. Effect of Addition of a Statin to Warfarin on Thromboembolic Events in Japanese Patients With Nonvalvular Atrial Fibrillation and Diabetes Mellitus. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28532776
  2. Teramoto T, Daida H, Ikewaki K et al. Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia. Atherosclerosis 2017; 261:69-77. http://www.ncbi.nlm.nih.gov/pubmed/?term=28478132
  3. Reith C, Staplin N, Herrington WG et al. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrol 2017; 18:147. http://www.ncbi.nlm.nih.gov/pubmed/?term=28460629
  4. Pokharel Y, Chinnakondepalli K, Vilain K et al. Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circ Cardiovasc Qual Outcomes 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506979
  5. Blackwood DP, LaVallee RK, Al Busaidi A et al. A randomized trial of the effects of ezetimibe on the absorption of omega-3 fatty acids in cardiac disease patients: A pilot study. Clinical nutrition ESPEN 2015; 10:e155-e159. http://www.ncbi.nlm.nih.gov/pubmed/?term=28531469
  6. Adhyaru BB, Jacobson TA. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations. Curr Atheroscler Rep 2017; 19:29. http://www.ncbi.nlm.nih.gov/pubmed/?term=28500517
  7. Anabtawi A, Moriarty PM, Miles JM. Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins. Current cardiology reports 2017; 19:62. http://www.ncbi.nlm.nih.gov/pubmed/?term=28528456
  8. Ferrari R, Aguiar C, Alegria E et al. Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. European heart journal supplements : journal of the European Society of Cardiology 2016; 18:C2-c12. http://www.ncbi.nlm.nih.gov/pubmed/?term=28533705
  9. Morelli VM, Lijfering WM, Bos MHA et al. Lipid levels and risk of venous thrombosis: results from the MEGA-study. European journal of epidemiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28540474
  10. Choby B. Diabetes Update: Prevention and Management of Diabetes Complications. FP essentials 2017; 456:36-40. http://www.ncbi.nlm.nih.gov/pubmed/?term=28530383
  11. Lin H, Zhang YM. The effect of Ezetimibe and Simvastatin Combination Therapy on percutaneous coronary intervention patients. Int J Cardiol 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28550977
  12. Stanifer JW, Charytan DM, White J et al. Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. Journal of the American Society of Nephrology : JASN 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28507057
  13. Offman E, Davidson M, Nilsson C. Assessment of pharmacokinetic interaction between omega-3 carboxylic acids and the statins rosuvastatin and simvastatin: Results of 2 phase I studies in healthy volunteers. J Clin Lipidol 2017; 11:739-748. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506390
  14. Ohta A, Kato H, Ishii S et al. Effect of Ezetimibe Monotherapy on Low-Density Lipoprotein Cholesterol and on Markers of Cholesterol Synthesis and Absorption in Japanese Patients With Hypercholesterolemia. Journal of clinical medicine research 2017; 9:476-481. http://www.ncbi.nlm.nih.gov/pubmed/?term=28496547
  15. Huang F, Marzin K, Koenen R et al. Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover Study. Journal of clinical pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28513969
  16. Deska P, Nowicki M. Short-term changes of serum potassium concentration induced by physical exercise in patient with arterial hypertension treated with angiotensin-converting enzyme inhibitor alone or in combination with statin. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 2017; 68:133-138. http://www.ncbi.nlm.nih.gov/pubmed/?term=28456777
  17. O'Donnell TFX, Deery SE, Darling JD et al. Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506476
  18. Japaridze L, Sadunishvili M. The short term effect of atorvastatin plus ezetimibe therapy vs. atorvastatin monotherapy on clinical outcome in the acute coronary syndrome patients by gender. Kardiol Pol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28553847
  19. Athyros VG, Alexandrides TK, Bilianou H et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017; 71:17-32. http://www.ncbi.nlm.nih.gov/pubmed/?term=28521870
  20. Wang P, Yang J, Yang Y, Ding Z. Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Pak J Med Sci 2017; 33:260-264. http://www.ncbi.nlm.nih.gov/pubmed/?term=28523018
  21. Chin LH, Hsu SP, Zhong WB, Liang YC. Correction: Combined Treatment with Troglitazone and Lovastatin Inhibited Epidermal Growth Factor-Induced Migration through the Downregulation of Cysteine-Rich Protein 61 in Human Anaplastic Thyroid Cancer Cells. PLoS One 2017; 12:e0177545. http://www.ncbi.nlm.nih.gov/pubmed/?term=28481927
  22. Luo F, Guo Y, Ruan GY et al. Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet. Scientific reports 2017; 7:2169. http://www.ncbi.nlm.nih.gov/pubmed/?term=28526884
  23. Wang H, Zhou J, Liu QZ et al. Simvastatin and Bezafibrate ameliorate Emotional disorder Induced by High fat diet in C57BL/6 mice. Scientific reports 2017; 7:2335. http://www.ncbi.nlm.nih.gov/pubmed/?term=28539670

Adherence

  1. Hsieh HC, Hsu JC, Lu CY. 10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database. BMJ Open 2017; 7:e014150. http://www.ncbi.nlm.nih.gov/pubmed/?term=28515189
  2. Lama S, Souraya D, Youssef F. Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients. Int J Clin Pharm 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28523462
  3. Silvennoinen R, Turunen JH, Kovanen PT et al. Attitudes and actions: A survey to assess statin use among Finnish patients with increased risk for cardiovascular events. J Clin Lipidol 2017; 11:485-494. http://www.ncbi.nlm.nih.gov/pubmed/?term=28502506
  4. Tjia J, Kutner JS, Ritchie CS et al. Perceptions of Statin Discontinuation among Patients with Life-Limiting Illness. Journal of palliative medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28520522
  5. Takata K, Psaltis PJ, Nicholls SJ. Investigating the long-term legacy of statin therapy. J Thorac Dis 2017; 9:936-939. http://www.ncbi.nlm.nih.gov/pubmed/?term=28523141
  6. An T, Hao J, Sun S et al. Statin treatment and healthy adherer effects. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28555284
  7. Nobre MRC, Domingues RZL. Patient adherence to ischemic heart disease treatment. Rev Assoc Med Bras (1992) 2017; 63:252-260. http://www.ncbi.nlm.nih.gov/pubmed/?term=28489132
  8. Malo S, Aguilar-Palacio I, Feja C et al. Persistence With Statins in Primary Prevention of Cardiovascular Disease: Findings From a Cohort of Spanish Workers. Rev Esp Cardiol (Engl Ed) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28473266 

Atherosclerosis & Imaging

  1. Li Z, Tian L, Liu J et al. Graphene Oxide/Ag Nanoparticles Cooperated with Simvastatin as a High Sensitive X-Ray Computed Tomography Imaging Agent for Diagnosis of Renal Dysfunctions. Advanced healthcare materials 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28564489
  2. Liu HY, Zhou J, Tong H et al. Quantitative evaluation of atherosclerotic plaques and intraplaque neovascularization using contrast-enhanced ultrasound after treatment with atorvastatin in rabbits. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017; 92:277-284. http://www.ncbi.nlm.nih.gov/pubmed/?term=28551548
  3. Hallengren E, Almgren P, Rosvall M et al. Fasting levels of growth hormone are associated with carotid intima media thickness but are not affected by fluvastatin treatment. BMC Cardiovasc Disord 2017; 17:125. http://www.ncbi.nlm.nih.gov/pubmed/?term=28511669
  4. Gamou T, Sakata K, Tada H et al. Effect of Reverse Vessel Remodeling on Regression of Coronary Atherosclerosis in Patients Treated With Aggressive Lipid- and Blood Pressure-Lowering Therapy- Insight From MILLION Study. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28515369
  5. Xing L, Higuma T, Wang Z et al. Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography: A 4-Year Follow-Up Study. J Am Coll Cardiol 2017; 69:2502-2513. http://www.ncbi.nlm.nih.gov/pubmed/?term=28521888
  6. Lee SH, Kim DH, Youn YN et al. Effect of Rosuvastatin on Bovine Pericardial Aortic Tissue Valve Calcification in a Rat Subdermal Implantation Model. Korean Circ J 2017; 47:401-408. http://www.ncbi.nlm.nih.gov/pubmed/?term=28567091
  7. Aday AW, Beckman JA. Medical Management of Asymptomatic Carotid Artery Stenosis. Prog Cardiovasc Dis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28539213 

Atorvastatin/Rosuvastatin

  1. Huang Q, Grabner M, Sanchez RJ et al. Clinical Characteristics and Unmet Need Among Patients with Atherosclerotic Cardiovascular Disease Stratified by Statin Use. American health & drug benefits 2016; 9:434-444. http://www.ncbi.nlm.nih.gov/pubmed/?term=28465771
  2. Hellberg S, Sippola S, Liljenback H et al. Effects of atorvastatin and diet interventions on atherosclerotic plaque inflammation and [18F]FDG uptake in Ldlr-/-Apob100/100 mice. Atherosclerosis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28457625
  3. Knight RA, Nagaraja TN, Li L et al. A Prospective Safety Trial of Atorvastatin Treatment to Assess Rebleeding after Spontaneous Intracerebral Hemorrhage: A Serial MRI Investigation. Austin journal of cerebrovascular disease & stroke 2016; 3. http://www.ncbi.nlm.nih.gov/pubmed/?term=28529979
  4. Peng P, Wei W, Long C, Li J. Atorvastatin augments temozolomide's efficacy in glioblastoma via prenylation-dependent inhibition of Ras signaling. Biochem Biophys Res Commun 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28554840
  5. Liu HY, Zhou J, Tong H et al. Quantitative evaluation of atherosclerotic plaques and intraplaque neovascularization using contrast-enhanced ultrasound after treatment with atorvastatin in rabbits. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017; 92:277-284. http://www.ncbi.nlm.nih.gov/pubmed/?term=28551548
  6. Auscher S, Logstrup BB, Moller JE et al. Effects of Intensive Statin Therapy on Left Ventricular Function in Patients with Myocardial Infarction and Abnormal Glucose Tolerance. Cardiology 2017; 138:16-25. http://www.ncbi.nlm.nih.gov/pubmed/?term=28514784
  7. Bayatmakoo R, Rashtchizadeh N, Yaghmaei P et al. Atorvastatin inhibits cholesterol-induced caspase-3 cleavage through down-regulation of p38 and up-regulation of Bcl-2 in the rat carotid artery. Cardiovascular journal of Africa 2017; 28:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28498386
  8. Bedi P, Chalmers JD, Graham C et al. A randomised control trial of atorvastatin in bronchiectasis patients infected with Pseudomonas aeruginosa- a proof of concept study. Chest 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28554732
  9. Gamou T, Sakata K, Tada H et al. Effect of Reverse Vessel Remodeling on Regression of Coronary Atherosclerosis in Patients Treated With Aggressive Lipid- and Blood Pressure-Lowering Therapy- Insight From MILLION Study. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28515369
  10. Ports WC, Fayyad R, DeMicco DA et al. Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis. Clinical drug investigation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28573499
  11. Varga Z, Nemcekova M, Carnicka S et al. Naproxen and Diclofenac Attenuate Atorvastatin-induced Preconditioning of the Myocardium. Cureus 2017; 9:e1201. http://www.ncbi.nlm.nih.gov/pubmed/?term=28560127
  12. El-Nabarawi N, El-Wakd M, Salem M. Atorvastatin, a double weapon in osteoporosis treatment: an experimental and clinical study. Drug design, development and therapy 2017; 11:1383-1391. http://www.ncbi.nlm.nih.gov/pubmed/?term=28496308
  13. Kim TE, Ha N, Kim Y et al. Effect of epigallocatechin-3-gallate, major ingredient of green tea, on the pharmacokinetics of rosuvastatin in healthy volunteers. Drug design, development and therapy 2017; 11:1409-1416. http://www.ncbi.nlm.nih.gov/pubmed/?term=28533679
  14. Thakkar D, Dash RP. Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Observations and introspection of the bioanalysis. Drug design, development and therapy 2017; 11:1263-1265. http://www.ncbi.nlm.nih.gov/pubmed/?term=28461740
  15. Rezen T, Hafner M, Kortagere S et al. Rosuvastatin and Atorvastatin are Ligands of the Human CAR/RXRalpha Complex. Drug metabolism and disposition: the biological fate of chemicals 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28536098
  16. Yoshikado T, Toshimoto K, Nakada T et al. Comparison of methods for estimating unbound intracellular-to-medium concentration ratios in rat and human hepatocytes using statins. Drug metabolism and disposition: the biological fate of chemicals 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28468836
  17. Schwartz GG, Fayyad R, Szarek M et al. Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome. Eur J Prev Cardiol 2017:2047487317708677. http://www.ncbi.nlm.nih.gov/pubmed/?term=28504565
  18. Cioboata R, Gaman A, Trasca D et al. Pharmacological management of non-alcoholic fatty liver disease: Atorvastatin versus pentoxifylline. Experimental and therapeutic medicine 2017; 13:2375-2381. http://www.ncbi.nlm.nih.gov/pubmed/?term=28565851
  19. Walker ME, Souza PR, Colas RA, Dalli J. 13-series resolvins mediate the leukocyte-platelet actions of atorvastatin and pravastatin in inflammatory arthritis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28465323
  20. Ovrakh T, Serik S, Kochubiei O. Impact of atorvastatin and rosuvastatin on residual on-clopidogrel treatment platelet reactivity in patients with ischemic heart disease and type 2 diabetes mellitus after acute coronary syndrome. Georgian medical news 2017:7-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=28574378 (Article in Russian)
  21. J BV, Ramakrishna S, Madhusudhan B. Preparation and characterisation of atorvastatin and curcumin-loaded chitosan nanoformulations for oral delivery in atherosclerosis. IET nanobiotechnology 2017; 11:96-103. http://www.ncbi.nlm.nih.gov/pubmed/?term=28476969
  22. Chua SHH, Tioleco GMS, Dayrit CAF et al. Atorvastatin as adjunctive therapy for chronic plaque type psoriasis versus betamethasone valerate alone: A randomized, double-blind, placebo-controlled trial. Indian journal of dermatology, venereology and leprology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28540870
  23. Lama S, Souraya D, Youssef F. Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients. Int J Clin Pharm 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28523462
  24. Olufade T, Zhou S, Anzalone D et al. Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28473405
  25. Bytyci I, Bajraktari G, Bhatt DL et al. Hydrophilic vs lipophilic statins in coronary artery disease: A meta-analysis of randomized controlled trials. J Clin Lipidol 2017; 11:624-637. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506385
  26. Offman E, Davidson M, Nilsson C. Assessment of pharmacokinetic interaction between omega-3 carboxylic acids and the statins rosuvastatin and simvastatin: Results of 2 phase I studies in healthy volunteers. J Clin Lipidol 2017; 11:739-748. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506390
  27. Wu CK, Yeh CF, Chiang JY et al. Effects of atorvastatin treatment on left ventricular diastolic function in peritoneal dialysis patients-The ALEVENT clinical trial. J Clin Lipidol 2017; 11:657-666. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506387
  28. Huang F, Marzin K, Koenen R et al. Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover Study. Journal of clinical pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28513969
  29. Kassem AM, Ibrahim HM, Samy AM. Development and Optimization of Atorvastatin Calcium loaded Self-nanoemulsifying Drug Delivery System (SNEDDS) for Enhancing Oral Bioavailability: in vitro and in vivo Evaluation. Journal of microencapsulation 2017:1-41. http://www.ncbi.nlm.nih.gov/pubmed/?term=28481663
  30. Benet LZ, Wu HF. Understanding the Potential Interethnic Difference in Rosuvastatin Pharmacokinetics. Journal of pharmaceutical sciences 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28502797
  31. Gabr MM, Mortada SM, Sallam MA. Hexagonal liquid crystalline nanodispersions proven superiority for enhanced oral delivery of rosuvastatin: in-vitro characterization and in-vivo pharmacokinetic study. Journal of pharmaceutical sciences 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28479357
  32. Sugiyama Y, Kazuya M, Toshimoto K. Is ethnic variability in the exposure to rosuvastatin explained only by genetic polymorphisms in OATP1B1 and BCRP or should the contribution of intrinsic ethnic differences in OATP1B1 be considered? Journal of pharmaceutical sciences 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28479351
  33. Yamashita S, Hasegawa T, Tachihara M et al. Quantitative Analysis of the Transporter Mediated drug-drug Interaction Between Atorvastatin and Rifampicin using a Stable Isotope-IV Method. Journal of pharmaceutical sciences 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28457720
  34. Heydari B, Khalili H, Beigmohammadi MT et al. Effects of atorvastatin on biomarkers of acute kidney injury in amikacin recipients: A pilot, randomized, placebo-controlled, clinical trial. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 2017; 22:39. http://www.ncbi.nlm.nih.gov/pubmed/?term=28465698
  35. O'Donnell TFX, Deery SE, Darling JD et al. Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506476
  36. Japaridze L, Sadunishvili M. The short term effect of atorvastatin plus ezetimibe therapy vs. atorvastatin monotherapy on clinical outcome in the acute coronary syndrome patients by gender. Kardiol Pol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28553847
  37. Lee SH, Kim DH, Youn YN et al. Effect of Rosuvastatin on Bovine Pericardial Aortic Tissue Valve Calcification in a Rat Subdermal Implantation Model. Korean Circ J 2017; 47:401-408. http://www.ncbi.nlm.nih.gov/pubmed/?term=28567091
  38. Gupta A, Thompson D, Whitehouse A et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28476288
  39. Pedro-Botet J, Rubies-Prat J. Statin-associated muscle symptoms: beware of the nocebo effect. Lancet 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28476289
  40. Choi SY, Park JS, Roh MS et al. Inhibition of Angiotensin II-Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice. Lipids 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28474247
  41. Bayat N, Izadpanah R, Ebrahimi-Barough S et al. Erratum to: Anti-inflammatory Effects of Atorvastatin in Human Glioblastoma Spheroids Cultured in a Three-dimensional Model: Possible Relevance to Glioblastoma Treatment. Mol Neurobiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28478505
  42. Li WK, Li H, Lu YF et al. Atorvastatin alters the expression of genes related to bile acid metabolism and circadian clock in livers of mice. PeerJ 2017; 5:e3348. http://www.ncbi.nlm.nih.gov/pubmed/?term=28533986
  43. Luo F, Guo Y, Ruan GY et al. Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet. Scientific reports 2017; 7:2169. http://www.ncbi.nlm.nih.gov/pubmed/?term=28526884
  44. Tian B, Al-Moujahed A, Bouzika P et al. Atorvastatin Promotes Phagocytosis and Attenuates Pro-Inflammatory Response in Human Retinal Pigment Epithelial Cells. Scientific reports 2017; 7:2329. http://www.ncbi.nlm.nih.gov/pubmed/?term=28539592 

Basic science

  1. Li Z, Tian L, Liu J et al. Graphene Oxide/Ag Nanoparticles Cooperated with Simvastatin as a High Sensitive X-Ray Computed Tomography Imaging Agent for Diagnosis of Renal Dysfunctions. Advanced healthcare materials 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28564489
  2. Hellberg S, Sippola S, Liljenback H et al. Effects of atorvastatin and diet interventions on atherosclerotic plaque inflammation and [18F]FDG uptake in Ldlr-/-Apob100/100 mice. Atherosclerosis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28457625
  3. Peng P, Wei W, Long C, Li J. Atorvastatin augments temozolomide's efficacy in glioblastoma via prenylation-dependent inhibition of Ras signaling. Biochem Biophys Res Commun 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28554840
  4. Huang W, Li Z, Zhao L, Zhao W. Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer's disease via modulating the expression of miR-106b. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017; 92:46-57. http://www.ncbi.nlm.nih.gov/pubmed/?term=28528185
  5. Liu HY, Zhou J, Tong H et al. Quantitative evaluation of atherosclerotic plaques and intraplaque neovascularization using contrast-enhanced ultrasound after treatment with atorvastatin in rabbits. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017; 92:277-284. http://www.ncbi.nlm.nih.gov/pubmed/?term=28551548
  6. Kamata T, Giblett S, Pritchard C. KRASG12D expression in lung-resident myeloid cells promotes pulmonary LCH-like neoplasm sensitive to statin treatment. Blood 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28550040
  7. Mansouri E, Jangaran A, Ashtari A. Protective effect of pravastatin on doxorubicin-induced hepatotoxicity. Bratislavske lekarske listy 2017; 118:273-277. http://www.ncbi.nlm.nih.gov/pubmed/?term=28516789
  8. Chowdhury K, Sharma A, Sharma T et al. Simvastatin and MBCD Inhibit Breast Cancer-Induced Osteoclast Activity by Targeting Osteoclastogenic Factors. Cancer investigation 2017:1-11. http://www.ncbi.nlm.nih.gov/pubmed/?term=28463564
  9. Bayatmakoo R, Rashtchizadeh N, Yaghmaei P et al. Atorvastatin inhibits cholesterol-induced caspase-3 cleavage through down-regulation of p38 and up-regulation of Bcl-2 in the rat carotid artery. Cardiovascular journal of Africa 2017; 28:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28498386
  10. Mouchrek Junior JCE, Macedo CG, Abdalla HB et al. Simvastatin modulates gingival cytokine and MMP production in a rat model of ligature-induced periodontitis. Clinical, cosmetic and investigational dentistry 2017; 9:33-38. http://www.ncbi.nlm.nih.gov/pubmed/?term=28553143
  11. Whitaker EJ, Alshammari A. Bacteriostatic Effect of Simvastatin on Selected Oral Streptococci in Vitro. Contemporary clinical dentistry 2017; 8:59-63. http://www.ncbi.nlm.nih.gov/pubmed/?term=28566853
  12. Antal I, Koneracka M, Zavisova V et al. Statins Determination: A Review of Electrochemical Techniques. Critical reviews in analytical chemistry 2017:0. http://www.ncbi.nlm.nih.gov/pubmed/?term=28548867
  13. Varga Z, Nemcekova M, Carnicka S et al. Naproxen and Diclofenac Attenuate Atorvastatin-induced Preconditioning of the Myocardium. Cureus 2017; 9:e1201. http://www.ncbi.nlm.nih.gov/pubmed/?term=28560127
  14. El-Nabarawi N, El-Wakd M, Salem M. Atorvastatin, a double weapon in osteoporosis treatment: an experimental and clinical study. Drug design, development and therapy 2017; 11:1383-1391. http://www.ncbi.nlm.nih.gov/pubmed/?term=28496308
  15. Rezen T, Hafner M, Kortagere S et al. Rosuvastatin and Atorvastatin are Ligands of the Human CAR/RXRalpha Complex. Drug metabolism and disposition: the biological fate of chemicals 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28536098
  16. Yoshikado T, Toshimoto K, Nakada T et al. Comparison of methods for estimating unbound intracellular-to-medium concentration ratios in rat and human hepatocytes using statins. Drug metabolism and disposition: the biological fate of chemicals 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28468836
  17. Yang Z, Su Z, DeWitt JP et al. Fluvastatin Prevents Lung Adenocarcinoma Bone Metastasis by Triggering Autophagy. EBioMedicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28454732
  18. An W, Han B, Li K et al. The protective study about alleviation of simvastatin on the damages of PEG-BNs in mice. Environmental toxicology and pharmacology 2017; 53:64-73. http://www.ncbi.nlm.nih.gov/pubmed/?term=28505473
  19. Doi H, Matsumoto S, Odawara S et al. Pravastatin reduces radiation-induced damage in normal tissues. Experimental and therapeutic medicine 2017; 13:1765-1772. http://www.ncbi.nlm.nih.gov/pubmed/?term=28565765
  20. Walker ME, Souza PR, Colas RA, Dalli J. 13-series resolvins mediate the leukocyte-platelet actions of atorvastatin and pravastatin in inflammatory arthritis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28465323
  21. Gum SI, Nguyen PA, Lee JR et al. The physico-chemical alteration of lovastatin and enhanced antioxidant effect of Bacillus subtilis fermented-red yeast rice product. Food chemistry 2017; 232:203-209. http://www.ncbi.nlm.nih.gov/pubmed/?term=28490066
  22. MacDougall DA, Pugh SD, Bassi HS et al. Simvastatin Promotes Cardiac Myocyte Relaxation in Association with Phosphorylation of Troponin I. Frontiers in pharmacology 2017; 8:203. http://www.ncbi.nlm.nih.gov/pubmed/?term=28469574
  23. Jin H, Welzig CM, Aronovitz M et al. QRS/T-Wave and Calcium Alternans in a Type I Diabetic Mouse Model for Spontaneous Post Myocardial Infarction Ventricular Tachycardia: A Mechanism for the Antiarrhythmic Effect of Statins. Heart rhythm 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28522367
  24. J BV, Ramakrishna S, Madhusudhan B. Preparation and characterisation of atorvastatin and curcumin-loaded chitosan nanoformulations for oral delivery in atherosclerosis. IET nanobiotechnology 2017; 11:96-103. http://www.ncbi.nlm.nih.gov/pubmed/?term=28476969
  25. Yamada Y, Takeuchi S, Yoneda M et al. Atorvastatin reduces cardiac and adipose tissue inflammation in rats with metabolic syndrome. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28499669
  26. Li R, Gan YH. Inhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-Ibeta Expression. Int J Mol Sci 2017; 18. http://www.ncbi.nlm.nih.gov/pubmed/?term=28481295
  27. Eftekhari BS, Karkhaneh A, Alizadeh A. Physically Targeted Intravenous Polyurethane Nanoparticles for Controlled Release of Atorvastatin Calcium. Iranian biomedical journal 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28532144
  28. Martins AF, Frank CDS, Altissimo J et al. Determination of statin drugs in hospital effluent with dispersive liquid-liquid microextraction and quantification by liquid chromatography. Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering 2017:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=28575579
  29. Kassem AM, Ibrahim HM, Samy AM. Development and Optimization of Atorvastatin Calcium loaded Self-nanoemulsifying Drug Delivery System (SNEDDS) for Enhancing Oral Bioavailability: in vitro and in vivo Evaluation. Journal of microencapsulation 2017:1-41. http://www.ncbi.nlm.nih.gov/pubmed/?term=28481663
  30. Rageh AH, Atia NN, Abdel-Rahman HM. Lipophilicity estimation of statins as a decisive physicochemical parameter for their hepato-selectivity using reversed-phase thin layer chromatography. Journal of pharmaceutical and biomedical analysis 2017; 142:7-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=28477451
  31. Gabr MM, Mortada SM, Sallam MA. Hexagonal liquid crystalline nanodispersions proven superiority for enhanced oral delivery of rosuvastatin: in-vitro characterization and in-vivo pharmacokinetic study. Journal of pharmaceutical sciences 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28479357
  32. Yamashita S, Hasegawa T, Tachihara M et al. Quantitative Analysis of the Transporter Mediated drug-drug Interaction Between Atorvastatin and Rifampicin using a Stable Isotope-IV Method. Journal of pharmaceutical sciences 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28457720
  33. Sato T, Mishima E, Mano N et al. Potential drug interactions mediated by renal organic anion transporter OATP4C1. J Pharmacol Exp Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28550055
  34. Kim EK, Cho JH, Jeong AR et al. Anti-inflammatory effects of simvastatin in nonsteroidal anti-inflammatory drugs-induced small bowel injury. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 2017; 68:69-77. http://www.ncbi.nlm.nih.gov/pubmed/?term=28456771
  35. Desai P, Helkin A, Odugbesi A et al. Fluvastatin inhibits intimal hyperplasia in wild-type but not Thbs1-null mice. J Surg Res 2017; 210:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=28457315
  36. Kapelouzou A, Giaglis S, Peroulis M et al. Overexpression of Toll-Like Receptors 2, 3, 4, and 8 Is Correlated to the Vascular Atherosclerotic Process in the Hyperlipidemic Rabbit Model: The Effect of Statin Treatment. Journal of vascular research 2017; 54:156-169. http://www.ncbi.nlm.nih.gov/pubmed/?term=28478461
  37. Lee SH, Kim DH, Youn YN et al. Effect of Rosuvastatin on Bovine Pericardial Aortic Tissue Valve Calcification in a Rat Subdermal Implantation Model. Korean Circ J 2017; 47:401-408. http://www.ncbi.nlm.nih.gov/pubmed/?term=28567091
  38. Choi SY, Park JS, Roh MS et al. Inhibition of Angiotensin II-Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice. Lipids 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28474247
  39. McFarland AJ, Davey AK, Anoopkumar-Dukie S. Statins Reduce Lipopolysaccharide-Induced Cytokine and Inflammatory Mediator Release in an In Vitro Model of Microglial-Like Cells. Mediators Inflamm 2017; 2017:2582745. http://www.ncbi.nlm.nih.gov/pubmed/?term=28546657
  40. Wang S, Xie X, Lei T et al. Statins Attenuate Activation of the NLRP3 Inflammasome by Oxidized-LDL or TNF-alpha in Vascular Endothelial Cells through a PXR-dependent mechanism. Molecular pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28546421
  41. Fang SC, Xie H, Chen F et al. Simvastatin ameliorates memory impairment and neurotoxicity in streptozotocin-induced diabetic mice. Neuroscience 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28499972
  42. Licarete E, Sesarman A, Rauca VF et al. HIF-1alpha acts as a molecular target for simvastatin cytotoxicity in B16.F10 melanoma cells cultured under chemically induced hypoxia. Oncology letters 2017; 13:3942-3950. http://www.ncbi.nlm.nih.gov/pubmed/?term=28521491
  43. Li WK, Li H, Lu YF et al. Atorvastatin alters the expression of genes related to bile acid metabolism and circadian clock in livers of mice. PeerJ 2017; 5:e3348. http://www.ncbi.nlm.nih.gov/pubmed/?term=28533986
  44. Shilpi D, Kushwah V, Agrawal AK, Jain S. Improved Stability and Enhanced Oral Bioavailability of Atorvastatin Loaded Stearic Acid Modified Gelatin Nanoparticles. Pharm Res 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28466393
  45. Ferri N, Marchiano S, Lupo MG et al. Geranylgeraniol prevents the simvastatin-induced PCSK9 expression: role of the small G protein Rac1. Pharmacol Res 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28554582
  46. Juneja M, Kobelt D, Walther W et al. Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via MACC1. PLoS biology 2017; 15:e2000784. http://www.ncbi.nlm.nih.gov/pubmed/?term=28570591
  47. Chin LH, Hsu SP, Zhong WB, Liang YC. Correction: Combined Treatment with Troglitazone and Lovastatin Inhibited Epidermal Growth Factor-Induced Migration through the Downregulation of Cysteine-Rich Protein 61 in Human Anaplastic Thyroid Cancer Cells. PLoS One 2017; 12:e0177545. http://www.ncbi.nlm.nih.gov/pubmed/?term=28481927
  48. Hwang AR, Han JH, Lim JH et al. Fluvastatin inhibits AGE-induced cell proliferation and migration via an ERK5-dependent Nrf2 pathway in vascular smooth muscle cells. PLoS One 2017; 12:e0178278. http://www.ncbi.nlm.nih.gov/pubmed/?term=28542559
  49. Nishimura S, Mishra-Gorur K, Park J et al. Combined HMG-COA reductase and prenylation inhibition in treatment of CCM. Proceedings of the National Academy of Sciences of the United States of America 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28500274
  50. Luo F, Guo Y, Ruan GY et al. Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet. Scientific reports 2017; 7:2169. http://www.ncbi.nlm.nih.gov/pubmed/?term=28526884
  51. Tian B, Al-Moujahed A, Bouzika P et al. Atorvastatin Promotes Phagocytosis and Attenuates Pro-Inflammatory Response in Human Retinal Pigment Epithelial Cells. Scientific reports 2017; 7:2329. http://www.ncbi.nlm.nih.gov/pubmed/?term=28539592
  52. Wang H, Zhou J, Liu QZ et al. Simvastatin and Bezafibrate ameliorate Emotional disorder Induced by High fat diet in C57BL/6 mice. Scientific reports 2017; 7:2335. http://www.ncbi.nlm.nih.gov/pubmed/?term=28539670
  53. Li Y, Xian M, Yang B et al. Inhibition of KLF4 by Statins Reverses Adriamycin-Induced Metastasis and Cancer Stemness in Osteosarcoma Cells. Stem cell reports 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28552603
  54. Yu SF, Cheng J, Geng S, Gao S. [Effects of simvastatin on the proliferation, invasion and radiosensitivity in Lewis lung cancer cell line]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 2017; 39:245-249. http://www.ncbi.nlm.nih.gov/pubmed/?term=28550662

Cancer

  1. Peng P, Wei W, Long C, Li J. Atorvastatin augments temozolomide's efficacy in glioblastoma via prenylation-dependent inhibition of Ras signaling. Biochem Biophys Res Commun 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28554840
  2. Kamata T, Giblett S, Pritchard C. KRASG12D expression in lung-resident myeloid cells promotes pulmonary LCH-like neoplasm sensitive to statin treatment. Blood 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28550040
  3. Gray RT, Loughrey MB, Bankhead P et al. Statin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study. Br J Cancer 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28524155
  4. Cardwell CR, Spence AD, Hughes CM, Murray LJ. Statin use after esophageal cancer diagnosis and survival: A population based cohort study. Cancer epidemiology 2017; 48:124-130. http://www.ncbi.nlm.nih.gov/pubmed/?term=28486205
  5. Chowdhury K, Sharma A, Sharma T et al. Simvastatin and MBCD Inhibit Breast Cancer-Induced Osteoclast Activity by Targeting Osteoclastogenic Factors. Cancer investigation 2017:1-11. http://www.ncbi.nlm.nih.gov/pubmed/?term=28463564
  6. Allott EH, Howard LE, Vidal AC et al. Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial. Cancer prevention research (Philadelphia, Pa.) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28487295
  7. Yang Z, Su Z, DeWitt JP et al. Fluvastatin Prevents Lung Adenocarcinoma Bone Metastasis by Triggering Autophagy. EBioMedicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28454732
  8. Voorneveld PW, Reimers MS, Bastiaannet E et al. Statin Use After Diagnosis of Colon Cancer and Patient Survival. Gastroenterology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28512021
  9. Li R, Gan YH. Inhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-Ibeta Expression. Int J Mol Sci 2017; 18. http://www.ncbi.nlm.nih.gov/pubmed/?term=28481295
  10. Lu VM, McDonald KL. The current evidence of statin use affecting glioblastoma prognosis. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28495423
  11. Bayat N, Izadpanah R, Ebrahimi-Barough S et al. Erratum to: Anti-inflammatory Effects of Atorvastatin in Human Glioblastoma Spheroids Cultured in a Three-dimensional Model: Possible Relevance to Glioblastoma Treatment. Mol Neurobiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28478505
  12. Xie W, Ning L, Huang Y et al. Statin use and survival outcomes in endocrine-related gynecologic cancers: A systematic review and meta-analysis. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28489569
  13. Juneja M, Kobelt D, Walther W et al. Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via MACC1. PLoS biology 2017; 15:e2000784. http://www.ncbi.nlm.nih.gov/pubmed/?term=28570591
  14. Nishimura S, Mishra-Gorur K, Park J et al. Combined HMG-COA reductase and prenylation inhibition in treatment of CCM. Proceedings of the National Academy of Sciences of the United States of America 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28500274
  15. Stensland K, McBride RB, Leapman M et al. Preoperative Statin Use Associated With Lower PSA But Similar Prostate Size and Histopathologic Outcomes: Implications for Active Surveillance? Urology journal 2017; 14:3064-3070. http://www.ncbi.nlm.nih.gov/pubmed/?term=28537044
  16. Yu SF, Cheng J, Geng S, Gao S. [Effects of simvastatin on the proliferation, invasion and radiosensitivity in Lewis lung cancer cell line]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 2017; 39:245-249. http://www.ncbi.nlm.nih.gov/pubmed/?term=28550662

Children

  1. Hennig M, Brandt A, Bautembach-Minkowska J et al. When do paediatric patients with familial hypercholesterolemia need statin therapy? Developmental period medicine 2017; 21:43-50. http://www.ncbi.nlm.nih.gov/pubmed/?term=28551692

CVD

  1. Huang Q, Grabner M, Sanchez RJ et al. Clinical Characteristics and Unmet Need Among Patients with Atherosclerotic Cardiovascular Disease Stratified by Statin Use. American health & drug benefits 2016; 9:434-444. http://www.ncbi.nlm.nih.gov/pubmed/?term=28465771
  2. Piao ZH, Jin L, Kim JH et al. Benefits of Statin Therapy in Patients With Acute Myocardial Infarction With Serum Low-Density Lipoprotein Cholesterol </= 50 mg/dl. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28532771
  3. Li R, White CM, Mehmeti J et al. Impact of a Perioperative Prophylaxis Guideline on Post-Cardiothoracic Surgery Atrial Fibrillation. The Annals of pharmacotherapy 2017:1060028017709290. http://www.ncbi.nlm.nih.gov/pubmed/?term=28511557
  4. Auscher S, Logstrup BB, Moller JE et al. Effects of Intensive Statin Therapy on Left Ventricular Function in Patients with Myocardial Infarction and Abnormal Glucose Tolerance. Cardiology 2017; 138:16-25. http://www.ncbi.nlm.nih.gov/pubmed/?term=28514784
  5. Schwartz GG, Fayyad R, Szarek M et al. Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome. Eur J Prev Cardiol 2017:2047487317708677. http://www.ncbi.nlm.nih.gov/pubmed/?term=28504565
  6. Lin H, Zhang YM. The effect of Ezetimibe and Simvastatin Combination Therapy on percutaneous coronary intervention patients. Int J Cardiol 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28550977
  7. Xing L, Higuma T, Wang Z et al. Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography: A 4-Year Follow-Up Study. J Am Coll Cardiol 2017; 69:2502-2513. http://www.ncbi.nlm.nih.gov/pubmed/?term=28521888
  8. Barnes BJ, Solomon S, Howard PA et al. Preoperative Statin use is not Associated with a Reduced Risk of Atrial Fibrillation After Cardiac Surgery. Journal of atrial fibrillation 2011; 4:325. http://www.ncbi.nlm.nih.gov/pubmed/?term=28496690
  9. Bytyci I, Bajraktari G, Bhatt DL et al. Hydrophilic vs lipophilic statins in coronary artery disease: A meta-analysis of randomized controlled trials. J Clin Lipidol 2017; 11:624-637. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506385
  10. Ling Y, Jiang J, Wu B, Gao X. Serum triglyceride, high-density lipoprotein cholesterol, apolipoprotein B, and coronary heart disease in a Chinese population undergoing coronary angiography. J Clin Lipidol 2017; 11:646-656. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506386
  11. Wu CK, Yeh CF, Chiang JY et al. Effects of atorvastatin treatment on left ventricular diastolic function in peritoneal dialysis patients-The ALEVENT clinical trial. J Clin Lipidol 2017; 11:657-666. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506387
  12. Han BH, Sutin D, Williamson JD et al. Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial. JAMA Intern Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28531241
  13. Choi SY, Park JS, Roh MS et al. Inhibition of Angiotensin II-Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice. Lipids 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28474247
  14. Yousef Yengej FA, Limper M, Leavis HL. Statins for prevention of cardiovascular disease in systemic lupus erythematosus. The Netherlands journal of medicine 2017; 75:99-105. http://www.ncbi.nlm.nih.gov/pubmed/?term=28469051

Endothelium/inflammation

  1. Hellberg S, Sippola S, Liljenback H et al. Effects of atorvastatin and diet interventions on atherosclerotic plaque inflammation and [18F]FDG uptake in Ldlr-/-Apob100/100 mice. Atherosclerosis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28457625
  2. Mouchrek Junior JCE, Macedo CG, Abdalla HB et al. Simvastatin modulates gingival cytokine and MMP production in a rat model of ligature-induced periodontitis. Clinical, cosmetic and investigational dentistry 2017; 9:33-38. http://www.ncbi.nlm.nih.gov/pubmed/?term=28553143
  3. Walker ME, Souza PR, Colas RA, Dalli J. 13-series resolvins mediate the leukocyte-platelet actions of atorvastatin and pravastatin in inflammatory arthritis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28465323
  4. Phillips KP. Role of Inflammation in Initiation and Perpetuation of Atrial Fibrillation: A Systematic Review of the Published Data. Journal of atrial fibrillation 2013; 6:935. http://www.ncbi.nlm.nih.gov/pubmed/?term=28496901
  5. Kim EK, Cho JH, Jeong AR et al. Anti-inflammatory effects of simvastatin in nonsteroidal anti-inflammatory drugs-induced small bowel injury. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 2017; 68:69-77. http://www.ncbi.nlm.nih.gov/pubmed/?term=28456771
  6. Desai P, Helkin A, Odugbesi A et al. Fluvastatin inhibits intimal hyperplasia in wild-type but not Thbs1-null mice. J Surg Res 2017; 210:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=28457315
  7. McFarland AJ, Davey AK, Anoopkumar-Dukie S. Statins Reduce Lipopolysaccharide-Induced Cytokine and Inflammatory Mediator Release in an In Vitro Model of Microglial-Like Cells. Mediators Inflamm 2017; 2017:2582745. http://www.ncbi.nlm.nih.gov/pubmed/?term=28546657
  8. Wang S, Xie X, Lei T et al. Statins Attenuate Activation of the NLRP3 Inflammasome by Oxidized-LDL or TNF-alpha in Vascular Endothelial Cells through a PXR-dependent mechanism. Molecular pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28546421
  9. Hwang AR, Han JH, Lim JH et al. Fluvastatin inhibits AGE-induced cell proliferation and migration via an ERK5-dependent Nrf2 pathway in vascular smooth muscle cells. PLoS One 2017; 12:e0178278. http://www.ncbi.nlm.nih.gov/pubmed/?term=28542559
  10. Tian B, Al-Moujahed A, Bouzika P et al. Atorvastatin Promotes Phagocytosis and Attenuates Pro-Inflammatory Response in Human Retinal Pigment Epithelial Cells. Scientific reports 2017; 7:2329. http://www.ncbi.nlm.nih.gov/pubmed/?term=28539592 

FH

  1. Hennig M, Brandt A, Bautembach-Minkowska J et al. When do paediatric patients with familial hypercholesterolemia need statin therapy? Developmental period medicine 2017; 21:43-50. http://www.ncbi.nlm.nih.gov/pubmed/?term=28551692
  2. Sbrana F, Dal Pino B, Bigazzi F et al. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else? Eur J Prev Cardiol 2017:2047487317712419. http://www.ncbi.nlm.nih.gov/pubmed/?term=28555526
  3. Marz W, Grammer TB, Delgado G, Kleber ME. [Congenital disorders of lipoprotein metabolism]. Herz 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28555288
  4. Galema-Boers AMH, Lenzen MJ, Sijbrands EJ, Roeters van Lennep JE. Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience. J Clin Lipidol 2017; 11:674-681. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506389
  5. Eslami SM, Nikfar S, Ghasemi M, Abdollahi M. Does Evolocumab, as a PCSK9 Inhibitor, Ameliorate the Lipid Profile in Familial Hypercholesterolemia Patients? A Meta-Analysis of Randomized Controlled Trials. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 2017; 20:81-96. http://www.ncbi.nlm.nih.gov/pubmed/?term=28459663   

Genetics

  1. Kitzmiller JP, Luzum JA, Dauki A et al. Candidate-Gene Study of Functional Polymorphisms in SLCO1B1 and CYP3A4/5 and the Cholesterol-Lowering Response to Simvastatin. Clinical and translational science 2017; 10:172-177. http://www.ncbi.nlm.nih.gov/pubmed/?term=28482130
  2. Thakkar D, Dash RP. Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Observations and introspection of the bioanalysis. Drug design, development and therapy 2017; 11:1263-1265. http://www.ncbi.nlm.nih.gov/pubmed/?term=28461740
  3. Sugiyama Y, Kazuya M, Toshimoto K. Is ethnic variability in the exposure to rosuvastatin explained only by genetic polymorphisms in OATP1B1 and BCRP or should the contribution of intrinsic ethnic differences in OATP1B1 be considered? Journal of pharmaceutical sciences 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28479351

Guidelines

  1. Li R, White CM, Mehmeti J et al. Impact of a Perioperative Prophylaxis Guideline on Post-Cardiothoracic Surgery Atrial Fibrillation. The Annals of pharmacotherapy 2017:1060028017709290. http://www.ncbi.nlm.nih.gov/pubmed/?term=28511557
  2. Graham IM, Catapano AL, Wong ND. Current guidelines on prevention with a focus on dyslipidemias. Cardiovascular diagnosis and therapy 2017; 7:S4-s10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28529917
  3. Adhyaru BB, Jacobson TA. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations. Curr Atheroscler Rep 2017; 19:29. http://www.ncbi.nlm.nih.gov/pubmed/?term=28500517
  4. Sinning D, Landmesser U. [Update Dyslipidaemias - Comments on the 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias]. Deutsche medizinische Wochenschrift (1946) 2017; 142:816-820. http://www.ncbi.nlm.nih.gov/pubmed/?term=28564733
  5. Housholder-Hughes SD, Martin MM, McFarland MR et al. Healthcare provider compliance with the 2013 ACC/AHA Adult Cholesterol Guideline recommendation for high-intensity dose statins for patients with coronary artery disease. Heart & lung : the journal of critical care 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28460888
  6. Whayne TF, Jr. Is There an Ideal Low-Density Lipoprotein Cholesterol Level? Confusion regarding Lipid Guidelines, Low-Density Lipoprotein Cholesterol Targets, and Medical Management. Int J Angiol 2017; 26:73-77. http://www.ncbi.nlm.nih.gov/pubmed/?term=28566931
  7. Kelly SG, Krueger KM, Grant JL et al. Statin prescribing practices in the comprehensive care for HIV-infected patients. J Acquir Immune Defic Syndr 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28520617
  8. Rosenson RS, Farkouh ME, Mefford M et al. Trends in Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011 to 2014. J Am Coll Cardiol 2017; 69:2696-2706. http://www.ncbi.nlm.nih.gov/pubmed/?term=28571633
  9. Olufade T, Zhou S, Anzalone D et al. Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28473405
  10. Qureshi WT, Kaplan RC, Swett K et al. American College of Cardiology/American Heart Association (ACC/AHA) Class I Guidelines for the Treatment of Cholesterol to Reduce Atherosclerotic Cardiovascular Risk: Implications for US Hispanics/Latinos Based on Findings From the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28495699
  11. Sarasua SM, Li J, Hernandez GT et al. Opportunities for improving cardiovascular health outcomes in adults younger than 65 years with guideline-recommended statin therapy. Journal of clinical hypertension (Greenwich, Conn.) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28480530
  12. O'Donnell TFX, Deery SE, Darling JD et al. Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506476
  13. Knopf HC, Busch MA, Du Y et al. [Changes in the prevalence of statin use in Germany - findings from national health interview and examination surveys 1997-1999 and 2008-2011]. Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28511896

LDL- related parameters

  1. Piao ZH, Jin L, Kim JH et al. Benefits of Statin Therapy in Patients With Acute Myocardial Infarction With Serum Low-Density Lipoprotein Cholesterol </= 50 mg/dl. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28532771
  2. Kostev K, Parhofer KG, Dippel FW. Prevalence of high-risk cardiovascular patients with therapy-resistant hypercholesterolemia. Cardiovascular endocrinology 2017; 6:81-85. http://www.ncbi.nlm.nih.gov/pubmed/?term=28540139
  3. Kampangkaew J, Pickett S, Nambi V. Advances in the management of dyslipidemia. Current opinion in cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28505047
  4. Lin H, Zhang YM. The effect of Ezetimibe and Simvastatin Combination Therapy on percutaneous coronary intervention patients. Int J Cardiol 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28550977
  5. Ling Y, Jiang J, Wu B, Gao X. Serum triglyceride, high-density lipoprotein cholesterol, apolipoprotein B, and coronary heart disease in a Chinese population undergoing coronary angiography. J Clin Lipidol 2017; 11:646-656. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506386
  6. Quinn AG, Schwemberger R, Stock EO et al. Moderate statin treatment reduces prebeta-1 high-density lipoprotein levels in dyslipidemic patients. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28558949

Meta-analyses

  1. Giacoppo D, Gargiulo G, Buccheri S et al. Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures: Evidence From a Hierarchical Bayesian Network Meta-Analysis of 124 Trials and 28 240 Patients. Circulation. Cardiovascular interventions 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28487354
  2. Kim RG, Loomba R, Prokop LJ, Singh S. Statin Use and Risk of Cirrhosis and Related Complications in Patients with Chronic Liver Diseases: a Systematic Review and Meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28479502
  3. Corrado A, Raviele A. Antiarrhythmic Effect of Statin Therapy and Atrial Fibrillation A Meta-Analysis of Randomized Controlled Trials. Journal of atrial fibrillation 2008; 1:50. http://www.ncbi.nlm.nih.gov/pubmed/?term=28496573
  4. Bytyci I, Bajraktari G, Bhatt DL et al. Hydrophilic vs lipophilic statins in coronary artery disease: A meta-analysis of randomized controlled trials. J Clin Lipidol 2017; 11:624-637. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506385
  5. Eslami SM, Nikfar S, Ghasemi M, Abdollahi M. Does Evolocumab, as a PCSK9 Inhibitor, Ameliorate the Lipid Profile in Familial Hypercholesterolemia Patients? A Meta-Analysis of Randomized Controlled Trials. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 2017; 20:81-96. http://www.ncbi.nlm.nih.gov/pubmed/?term=28459663
  6. Wang S, Yao H, Yu H et al. Effect of perioperative statin therapy on renal outcome in patients undergoing cardiac surgery: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2017; 96:e6883. http://www.ncbi.nlm.nih.gov/pubmed/?term=28489791
  7. Yousef Yengej FA, Limper M, Leavis HL. Statins for prevention of cardiovascular disease in systemic lupus erythematosus. The Netherlands journal of medicine 2017; 75:99-105. http://www.ncbi.nlm.nih.gov/pubmed/?term=28469051
  8. Xie W, Ning L, Huang Y et al. Statin use and survival outcomes in endocrine-related gynecologic cancers: A systematic review and meta-analysis. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28489569
  9. Chen M, Lu J, Chen Q et al. [Statin in the treatment of ALI/ARDS: a systematic review and Meta-analysis based on international databases]. Zhonghua wei zhong bing ji jiu yi xue 2017; 29:51-56. http://www.ncbi.nlm.nih.gov/pubmed/?term=28459404

Metabolic Syndrome - Diabetes

  1. Kumagai N, Nusser JA, Inoue H et al. Effect of Addition of a Statin to Warfarin on Thromboembolic Events in Japanese Patients With Nonvalvular Atrial Fibrillation and Diabetes Mellitus. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28532776
  2. Hsieh HC, Hsu JC, Lu CY. 10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database. BMJ Open 2017; 7:e014150. http://www.ncbi.nlm.nih.gov/pubmed/?term=28515189
  3. Muller-Wieland D, Leiter LA, Cariou B et al. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. Cardiovascular diabetology 2017; 16:70. http://www.ncbi.nlm.nih.gov/pubmed/?term=28545518
  4. Anabtawi A, Moriarty PM, Miles JM. Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins. Current cardiology reports 2017; 19:62. http://www.ncbi.nlm.nih.gov/pubmed/?term=28528456
  5. Choby B. Diabetes Update: Prevention and Management of Diabetes Complications. FP essentials 2017; 456:36-40. http://www.ncbi.nlm.nih.gov/pubmed/?term=28530383
  6. Yamada Y, Takeuchi S, Yoneda M et al. Atorvastatin reduces cardiac and adipose tissue inflammation in rats with metabolic syndrome. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28499669
  7. Gamboa CM, Colantonio LD, Brown TM et al. Race-Sex Differences in Statin Use and Low-Density Lipoprotein Cholesterol Control Among People With Diabetes Mellitus in the Reasons for Geographic and Racial Differences in Stroke Study. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28490523

New Treatments

  1. Landray MJ, Reveal Collaborative G. Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. Am Heart J 2017; 187:182-190. http://www.ncbi.nlm.nih.gov/pubmed/?term=28454801
  2. Teramoto T, Daida H, Ikewaki K et al. Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia. Atherosclerosis 2017; 261:69-77. http://www.ncbi.nlm.nih.gov/pubmed/?term=28478132
  3. Muller-Wieland D, Leiter LA, Cariou B et al. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. Cardiovascular diabetology 2017; 16:70. http://www.ncbi.nlm.nih.gov/pubmed/?term=28545518
  4. Wong ND, Rosenblit PD, Greenfield RS. Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyond. Cardiovascular diagnosis and therapy 2017; 7:S11-s20. http://www.ncbi.nlm.nih.gov/pubmed/?term=28529918
  5. Yokote K, Kanada S, Matsuoka O et al. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive- Results From a Randomized, Placebo-Controlled, Dose-Ranging Study. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28539539
  6. Kampangkaew J, Pickett S, Nambi V. Advances in the management of dyslipidemia. Current opinion in cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28505047
  7. Pandey AS, Bajaj HS, Garg V et al. The emerging role of proprotein convertase subtilisin/kexin type-9 inhibition in secondary prevention: from clinical trials to real-world experience. Current opinion in cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28557865
  8. Soran H, Kwok S, Adam S et al. Evidence for more intensive cholesterol lowering. Curr Opin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28509674
  9. Chang Y, Robidoux J. Dyslipidemia management update. Current opinion in pharmacology 2017; 33:47-55. http://www.ncbi.nlm.nih.gov/pubmed/?term=28527325
  10. Sbrana F, Dal Pino B, Bigazzi F et al. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else? Eur J Prev Cardiol 2017:2047487317712419. http://www.ncbi.nlm.nih.gov/pubmed/?term=28555526
  11. Whayne TF, Jr. Is There an Ideal Low-Density Lipoprotein Cholesterol Level? Confusion regarding Lipid Guidelines, Low-Density Lipoprotein Cholesterol Targets, and Medical Management. Int J Angiol 2017; 26:73-77. http://www.ncbi.nlm.nih.gov/pubmed/?term=28566931
  12. Cohen JD, Cziraky MJ, Jacobson TA et al. Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28550993
  13. Galema-Boers AMH, Lenzen MJ, Sijbrands EJ, Roeters van Lennep JE. Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience. J Clin Lipidol 2017; 11:674-681. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506389
  14. Orringer CE, Jacobson TA, Saseen JJ et al. Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28532784
  15. Eslami SM, Nikfar S, Ghasemi M, Abdollahi M. Does Evolocumab, as a PCSK9 Inhibitor, Ameliorate the Lipid Profile in Familial Hypercholesterolemia Patients? A Meta-Analysis of Randomized Controlled Trials. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 2017; 20:81-96. http://www.ncbi.nlm.nih.gov/pubmed/?term=28459663
  16. Ferri N, Marchiano S, Lupo MG et al. Geranylgeraniol prevents the simvastatin-induced PCSK9 expression: role of the small G protein Rac1. Pharmacol Res 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28554582 

PAD and statins

  1. Bader AP, Barone CP, Smeds MR. Risk factor modification behaviors of practicing vascular surgeons. Annals of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28572029
  2. Abtan J, Bhatt DL, Elbez Y et al. Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry. Clin Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28520087
  3. Berger JS, Ladapo JA. Underuse of Prevention and Lifestyle Counseling in Patients With Peripheral Artery Disease. J Am Coll Cardiol 2017; 69:2293-2300. http://www.ncbi.nlm.nih.gov/pubmed/?term=28473134
  4. Hiatt WR, Rogers RK. The Treatment Gap in Peripheral Artery Disease. J Am Coll Cardiol 2017; 69:2301-2303. http://www.ncbi.nlm.nih.gov/pubmed/?term=28473135
  5. O'Donnell TFX, Deery SE, Darling JD et al. Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506476
  6. Ratchford EV. Medical management of claudication. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28533077

Pleiotropic effects of statins

  1. Iraji F, Banihashemi SH, Faghihi G et al. A Comparison of Betamethasone Valerate 0.1% Cream Twice Daily Plus Oral Simvastatin Versus Betamethasone Valerate 0.1% Cream Alone in the Treatment of Vitiligo Patients. Advanced biomedical research 2017; 6:34. http://www.ncbi.nlm.nih.gov/pubmed/?term=28516068
  2. Vangala C, Lenihan CR, Montez-Rath ME et al. Statin use and hip fractures in U.S. kidney transplant recipients. BMC Nephrol 2017; 18:145. http://www.ncbi.nlm.nih.gov/pubmed/?term=28460645
  3. Mansouri E, Jangaran A, Ashtari A. Protective effect of pravastatin on doxorubicin-induced hepatotoxicity. Bratislavske lekarske listy 2017; 118:273-277. http://www.ncbi.nlm.nih.gov/pubmed/?term=28516789
  4. Allott EH, Howard LE, Vidal AC et al. Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial. Cancer prevention research (Philadelphia, Pa.) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28487295
  5. Bedi P, Chalmers JD, Graham C et al. A randomised control trial of atorvastatin in bronchiectasis patients infected with Pseudomonas aeruginosa- a proof of concept study. Chest 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28554732
  6. Su VY, Su WJ, Yen YF et al. Statin Use is Associated with a Lower Risk of Tuberculosis. Chest 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28479115
  7. Giacoppo D, Gargiulo G, Buccheri S et al. Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures: Evidence From a Hierarchical Bayesian Network Meta-Analysis of 124 Trials and 28 240 Patients. Circulation. Cardiovascular interventions 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28487354
  8. Ports WC, Fayyad R, DeMicco DA et al. Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis. Clinical drug investigation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28573499
  9. Kim RG, Loomba R, Prokop LJ, Singh S. Statin Use and Risk of Cirrhosis and Related Complications in Patients with Chronic Liver Diseases: a Systematic Review and Meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28479502
  10. Caldwell S. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. Clinical and molecular hepatology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28494529
  11. Whitaker EJ, Alshammari A. Bacteriostatic Effect of Simvastatin on Selected Oral Streptococci in Vitro. Contemporary clinical dentistry 2017; 8:59-63. http://www.ncbi.nlm.nih.gov/pubmed/?term=28566853
  12. Agus A, Hulme C, Verghis RM et al. Simvastatin for patients with acute respiratory distress syndrome: long-term outcomes and cost-effectiveness from a randomised controlled trial. Crit Care 2017; 21:108. http://www.ncbi.nlm.nih.gov/pubmed/?term=28511660
  13. Varga Z, Nemcekova M, Carnicka S et al. Naproxen and Diclofenac Attenuate Atorvastatin-induced Preconditioning of the Myocardium. Cureus 2017; 9:e1201. http://www.ncbi.nlm.nih.gov/pubmed/?term=28560127
  14. El-Nabarawi N, El-Wakd M, Salem M. Atorvastatin, a double weapon in osteoporosis treatment: an experimental and clinical study. Drug design, development and therapy 2017; 11:1383-1391. http://www.ncbi.nlm.nih.gov/pubmed/?term=28496308
  15. An W, Han B, Li K et al. The protective study about alleviation of simvastatin on the damages of PEG-BNs in mice. Environmental toxicology and pharmacology 2017; 53:64-73. http://www.ncbi.nlm.nih.gov/pubmed/?term=28505473
  16. Morelli VM, Lijfering WM, Bos MHA et al. Lipid levels and risk of venous thrombosis: results from the MEGA-study. European journal of epidemiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28540474
  17. Cioboata R, Gaman A, Trasca D et al. Pharmacological management of non-alcoholic fatty liver disease: Atorvastatin versus pentoxifylline. Experimental and therapeutic medicine 2017; 13:2375-2381. http://www.ncbi.nlm.nih.gov/pubmed/?term=28565851
  18. Doi H, Matsumoto S, Odawara S et al. Pravastatin reduces radiation-induced damage in normal tissues. Experimental and therapeutic medicine 2017; 13:1765-1772. http://www.ncbi.nlm.nih.gov/pubmed/?term=28565765
  19. Sehra D, Sehra S, Sehra ST. Cardiovascular pleiotropic effects of statins and new onset diabetes: is there a common link: do we need to evaluate the role of KATP Channels? Expert opinion on drug safety 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28571494
  20. Katsi V, Georgountzos G, Kallistratos MS et al. The Role of Statins in Prevention of Preeclampsia: A Promise for the Future? Frontiers in pharmacology 2017; 8:247. http://www.ncbi.nlm.nih.gov/pubmed/?term=28529486
  21. Lin CJ, Liao WC, Chen YA et al. Statin Therapy Is Associated with Reduced Risk of Peptic Ulcer Disease in the Taiwanese Population. Frontiers in pharmacology 2017; 8:210. http://www.ncbi.nlm.nih.gov/pubmed/?term=28503146
  22. MacDougall DA, Pugh SD, Bassi HS et al. Simvastatin Promotes Cardiac Myocyte Relaxation in Association with Phosphorylation of Troponin I. Frontiers in pharmacology 2017; 8:203. http://www.ncbi.nlm.nih.gov/pubmed/?term=28469574
  23. Jin H, Welzig CM, Aronovitz M et al. QRS/T-Wave and Calcium Alternans in a Type I Diabetic Mouse Model for Spontaneous Post Myocardial Infarction Ventricular Tachycardia: A Mechanism for the Antiarrhythmic Effect of Statins. Heart rhythm 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28522367
  24. Chua SHH, Tioleco GMS, Dayrit CAF et al. Atorvastatin as adjunctive therapy for chronic plaque type psoriasis versus betamethasone valerate alone: A randomized, double-blind, placebo-controlled trial. Indian journal of dermatology, venereology and leprology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28540870
  25. Corrado A, Raviele A. Antiarrhythmic Effect of Statin Therapy and Atrial Fibrillation A Meta-Analysis of Randomized Controlled Trials. Journal of atrial fibrillation 2008; 1:50. http://www.ncbi.nlm.nih.gov/pubmed/?term=28496573
  26. Fauchier L, Clementy N, Pierre B, Babuty D. Statin and Atrial Fibrilation: When does it work? Journal of atrial fibrillation 2012; 5:443. http://www.ncbi.nlm.nih.gov/pubmed/?term=28496754
  27. Paturi A, Shukla A, Ebra G et al. Do Statins Reduce Atrial Fibrillation After Coronary Artery Bypass Grafting? Journal of atrial fibrillation 2011; 4:347. http://www.ncbi.nlm.nih.gov/pubmed/?term=28496694
  28. Phillips KP. Role of Inflammation in Initiation and Perpetuation of Atrial Fibrillation: A Systematic Review of the Published Data. Journal of atrial fibrillation 2013; 6:935. http://www.ncbi.nlm.nih.gov/pubmed/?term=28496901
  29. Bril F, Portillo Sanchez P, Lomonaco R et al. Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post-hoc Analysis of a Randomized Trial. J Clin Endocrinol Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28575232
  30. Cassidy-Vu L, Joe E, Kirk JK. Role of Statin Drugs for Polycystic Ovary Syndrome. Journal of family & reproductive health 2016; 10:165-175. http://www.ncbi.nlm.nih.gov/pubmed/?term=28546815
  31. Raphael J, Collins SR, Wang XQ et al. Perioperative statin use is associated with decreased incidence of primary graft dysfunction after lung transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28552627
  32. Kim EK, Cho JH, Jeong AR et al. Anti-inflammatory effects of simvastatin in nonsteroidal anti-inflammatory drugs-induced small bowel injury. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 2017; 68:69-77. http://www.ncbi.nlm.nih.gov/pubmed/?term=28456771
  33. Heydari B, Khalili H, Beigmohammadi MT et al. Effects of atorvastatin on biomarkers of acute kidney injury in amikacin recipients: A pilot, randomized, placebo-controlled, clinical trial. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 2017; 22:39. http://www.ncbi.nlm.nih.gov/pubmed/?term=28465698
  34. Wang S, Yao H, Yu H et al. Effect of perioperative statin therapy on renal outcome in patients undergoing cardiac surgery: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2017; 96:e6883. http://www.ncbi.nlm.nih.gov/pubmed/?term=28489791
  35. Athyros VG, Alexandrides TK, Bilianou H et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017; 71:17-32. http://www.ncbi.nlm.nih.gov/pubmed/?term=28521870
  36. An T, Hao J, Sun S et al. Statin treatment and healthy adherer effects. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28555284
  37. Donzelli A, Battaggia A, Schivalocchi A. Statin use does not protect from fractures: the healthy adherer effect is a plausible explanation in observational studies. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28555283
  38. Wang P, Yang J, Yang Y, Ding Z. Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Pak J Med Sci 2017; 33:260-264. http://www.ncbi.nlm.nih.gov/pubmed/?term=28523018
  39. Li WK, Li H, Lu YF et al. Atorvastatin alters the expression of genes related to bile acid metabolism and circadian clock in livers of mice. PeerJ 2017; 5:e3348. http://www.ncbi.nlm.nih.gov/pubmed/?term=28533986
  40. Stensland K, McBride RB, Leapman M et al. Preoperative Statin Use Associated With Lower PSA But Similar Prostate Size and Histopathologic Outcomes: Implications for Active Surveillance? Urology journal 2017; 14:3064-3070. http://www.ncbi.nlm.nih.gov/pubmed/?term=28537044
  41. Chen M, Lu J, Chen Q et al. [Statin in the treatment of ALI/ARDS: a systematic review and Meta-analysis based on international databases]. Zhonghua wei zhong bing ji jiu yi xue 2017; 29:51-56. http://www.ncbi.nlm.nih.gov/pubmed/?term=28459404

Primary Prevention

  1. Hasegawa T, Zhao J, Fuller DS et al. Erythropoietin Hyporesponsiveness in Dialysis Patients: Possible Role of Statins. Am J Nephrol 2017; 46:11-17. http://www.ncbi.nlm.nih.gov/pubmed/?term=28564644
  2. Umeh G, Huffman MD. Challenges and opportunities in accessing trial data: an example from statin primary prevention trials. Heart Asia 2017; 9:99-101. http://www.ncbi.nlm.nih.gov/pubmed/?term=28469714
  3. Han BH, Sutin D, Williamson JD et al. Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial. JAMA Intern Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28531241
  4. Malo S, Aguilar-Palacio I, Feja C et al. Persistence With Statins in Primary Prevention of Cardiovascular Disease: Findings From a Cohort of Spanish Workers. Rev Esp Cardiol (Engl Ed) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28473266

Registry data

  1. Huang Q, Grabner M, Sanchez RJ et al. Clinical Characteristics and Unmet Need Among Patients with Atherosclerotic Cardiovascular Disease Stratified by Statin Use. American health & drug benefits 2016; 9:434-444. http://www.ncbi.nlm.nih.gov/pubmed/?term=28465771
  2. Kumagai N, Nusser JA, Inoue H et al. Effect of Addition of a Statin to Warfarin on Thromboembolic Events in Japanese Patients With Nonvalvular Atrial Fibrillation and Diabetes Mellitus. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28532776
  3. Piao ZH, Jin L, Kim JH et al. Benefits of Statin Therapy in Patients With Acute Myocardial Infarction With Serum Low-Density Lipoprotein Cholesterol </= 50 mg/dl. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28532771
  4. Kokkinos P, Faselis C, Narayan P et al. Cardiorespiratory Fitness and Incidence of Type 2 Diabetes in United States Veterans on Statin Therapy. Am J Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28552431
  5. Hallengren E, Almgren P, Rosvall M et al. Fasting levels of growth hormone are associated with carotid intima media thickness but are not affected by fluvastatin treatment. BMC Cardiovasc Disord 2017; 17:125. http://www.ncbi.nlm.nih.gov/pubmed/?term=28511669
  6. Hsieh HC, Hsu JC, Lu CY. 10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database. BMJ Open 2017; 7:e014150. http://www.ncbi.nlm.nih.gov/pubmed/?term=28515189
  7. Cardwell CR, Spence AD, Hughes CM, Murray LJ. Statin use after esophageal cancer diagnosis and survival: A population based cohort study. Cancer epidemiology 2017; 48:124-130. http://www.ncbi.nlm.nih.gov/pubmed/?term=28486205
  8. Kostev K, Parhofer KG, Dippel FW. Prevalence of high-risk cardiovascular patients with therapy-resistant hypercholesterolemia. Cardiovascular endocrinology 2017; 6:81-85. http://www.ncbi.nlm.nih.gov/pubmed/?term=28540139
  9. Su VY, Su WJ, Yen YF et al. Statin Use is Associated with a Lower Risk of Tuberculosis. Chest 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28479115
  10. Gamou T, Sakata K, Tada H et al. Effect of Reverse Vessel Remodeling on Regression of Coronary Atherosclerosis in Patients Treated With Aggressive Lipid- and Blood Pressure-Lowering Therapy- Insight From MILLION Study. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28515369
  11. Abtan J, Bhatt DL, Elbez Y et al. Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry. Clin Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28520087
  12. Lin CJ, Liao WC, Chen YA et al. Statin Therapy Is Associated with Reduced Risk of Peptic Ulcer Disease in the Taiwanese Population. Frontiers in pharmacology 2017; 8:210. http://www.ncbi.nlm.nih.gov/pubmed/?term=28503146
  13. Voorneveld PW, Reimers MS, Bastiaannet E et al. Statin Use After Diagnosis of Colon Cancer and Patient Survival. Gastroenterology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28512021
  14. Housholder-Hughes SD, Martin MM, McFarland MR et al. Healthcare provider compliance with the 2013 ACC/AHA Adult Cholesterol Guideline recommendation for high-intensity dose statins for patients with coronary artery disease. Heart & lung : the journal of critical care 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28460888
  15. Lama S, Souraya D, Youssef F. Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients. Int J Clin Pharm 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28523462
  16. Berger JS, Ladapo JA. Underuse of Prevention and Lifestyle Counseling in Patients With Peripheral Artery Disease. J Am Coll Cardiol 2017; 69:2293-2300. http://www.ncbi.nlm.nih.gov/pubmed/?term=28473134
  17. Hiatt WR, Rogers RK. The Treatment Gap in Peripheral Artery Disease. J Am Coll Cardiol 2017; 69:2301-2303. http://www.ncbi.nlm.nih.gov/pubmed/?term=28473135
  18. Rosenson RS, Farkouh ME, Mefford M et al. Trends in Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011 to 2014. J Am Coll Cardiol 2017; 69:2696-2706. http://www.ncbi.nlm.nih.gov/pubmed/?term=28571633
  19. Gamboa CM, Colantonio LD, Brown TM et al. Race-Sex Differences in Statin Use and Low-Density Lipoprotein Cholesterol Control Among People With Diabetes Mellitus in the Reasons for Geographic and Racial Differences in Stroke Study. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28490523
  20. Olufade T, Zhou S, Anzalone D et al. Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28473405
  21. Barnes BJ, Solomon S, Howard PA et al. Preoperative Statin use is not Associated with a Reduced Risk of Atrial Fibrillation After Cardiac Surgery. Journal of atrial fibrillation 2011; 4:325. http://www.ncbi.nlm.nih.gov/pubmed/?term=28496690
  22. Paturi A, Shukla A, Ebra G et al. Do Statins Reduce Atrial Fibrillation After Coronary Artery Bypass Grafting? Journal of atrial fibrillation 2011; 4:347. http://www.ncbi.nlm.nih.gov/pubmed/?term=28496694
  23. Chung CM, Lin MS, Hsu JT et al. Effects of statin therapy on cerebrovascular and renal outcomes in patients with predialysis advanced chronic kidney disease and dyslipidemia. J Clin Lipidol 2017; 11:422-431.e422. http://www.ncbi.nlm.nih.gov/pubmed/?term=28502499
  24. Galema-Boers AMH, Lenzen MJ, Sijbrands EJ, Roeters van Lennep JE. Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience. J Clin Lipidol 2017; 11:674-681. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506389
  25. Ling Y, Jiang J, Wu B, Gao X. Serum triglyceride, high-density lipoprotein cholesterol, apolipoprotein B, and coronary heart disease in a Chinese population undergoing coronary angiography. J Clin Lipidol 2017; 11:646-656. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506386
  26. O'Donnell TFX, Deery SE, Darling JD et al. Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506476
  27. Kim TM, Kim H, Jeong YJ et al. The differences in the incidence of diabetes mellitus and prediabetes according to the type of HMG-CoA reductase inhibitors prescribed in Korean patients. Pharmacoepidemiol Drug Saf 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28556206
  28. Malo S, Aguilar-Palacio I, Feja C et al. Persistence With Statins in Primary Prevention of Cardiovascular Disease: Findings From a Cohort of Spanish Workers. Rev Esp Cardiol (Engl Ed) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28473266
  29. Knopf HC, Busch MA, Du Y et al. [Changes in the prevalence of statin use in Germany - findings from national health interview and examination surveys 1997-1999 and 2008-2011]. Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28511896

Renal Disease

  1. Vangala C, Lenihan CR, Montez-Rath ME et al. Statin use and hip fractures in U.S. kidney transplant recipients. BMC Nephrol 2017; 18:145. http://www.ncbi.nlm.nih.gov/pubmed/?term=28460645
  2. Giacoppo D, Gargiulo G, Buccheri S et al. Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures: Evidence From a Hierarchical Bayesian Network Meta-Analysis of 124 Trials and 28 240 Patients. Circulation. Cardiovascular interventions 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28487354
  3. Brosnahan G, Abebe KZ, Rahbari-Oskoui FF et al. Effect of statin therapy on the progression of autosomal dominant polycystic kidney disease. A secondary analysis of the HALT PKD trials. Current hypertension reviews 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28460625
  4. Stanifer JW, Charytan DM, White J et al. Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. Journal of the American Society of Nephrology : JASN 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28507057
  5. Chung CM, Lin MS, Hsu JT et al. Effects of statin therapy on cerebrovascular and renal outcomes in patients with predialysis advanced chronic kidney disease and dyslipidemia. J Clin Lipidol 2017; 11:422-431.e422. http://www.ncbi.nlm.nih.gov/pubmed/?term=28502499
  6. Heydari B, Khalili H, Beigmohammadi MT et al. Effects of atorvastatin on biomarkers of acute kidney injury in amikacin recipients: A pilot, randomized, placebo-controlled, clinical trial. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 2017; 22:39. http://www.ncbi.nlm.nih.gov/pubmed/?term=28465698
  7. Wang S, Yao H, Yu H et al. Effect of perioperative statin therapy on renal outcome in patients undergoing cardiac surgery: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2017; 96:e6883. http://www.ncbi.nlm.nih.gov/pubmed/?term=28489791 

Reviews

  1. Bader AP, Barone CP, Smeds MR. Risk factor modification behaviors of practicing vascular surgeons. Annals of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28572029
  2. Graham IM, Catapano AL, Wong ND. Current guidelines on prevention with a focus on dyslipidemias. Cardiovascular diagnosis and therapy 2017; 7:S4-s10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28529917
  3. Wong ND, Rosenblit PD, Greenfield RS. Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyond. Cardiovascular diagnosis and therapy 2017; 7:S11-s20. http://www.ncbi.nlm.nih.gov/pubmed/?term=28529918
  4. Caldwell S. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. Clinical and molecular hepatology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28494529
  5. Anabtawi A, Moriarty PM, Miles JM. Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins. Current cardiology reports 2017; 19:62. http://www.ncbi.nlm.nih.gov/pubmed/?term=28528456
  6. Raparelli V, Pannitteri G, Todisco T et al. Treatment and Response to Statins: Gender-related Differences. Curr Med Chem 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28552051
  7. Kampangkaew J, Pickett S, Nambi V. Advances in the management of dyslipidemia. Current opinion in cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28505047
  8. Pandey AS, Bajaj HS, Garg V et al. The emerging role of proprotein convertase subtilisin/kexin type-9 inhibition in secondary prevention: from clinical trials to real-world experience. Current opinion in cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28557865
  9. Soran H, Kwok S, Adam S et al. Evidence for more intensive cholesterol lowering. Curr Opin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28509674
  10. Chang Y, Robidoux J. Dyslipidemia management update. Current opinion in pharmacology 2017; 33:47-55. http://www.ncbi.nlm.nih.gov/pubmed/?term=28527325
  11. Ferrari R, Aguiar C, Alegria E et al. Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. European heart journal supplements : journal of the European Society of Cardiology 2016; 18:C2-c12. http://www.ncbi.nlm.nih.gov/pubmed/?term=28533705
  12. Schwartz GG, Fayyad R, Szarek M et al. Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome. Eur J Prev Cardiol 2017:2047487317708677. http://www.ncbi.nlm.nih.gov/pubmed/?term=28504565
  13. Choby B. Diabetes Update: Prevention and Management of Diabetes Complications. FP essentials 2017; 456:36-40. http://www.ncbi.nlm.nih.gov/pubmed/?term=28530383
  14. Katsi V, Georgountzos G, Kallistratos MS et al. The Role of Statins in Prevention of Preeclampsia: A Promise for the Future? Frontiers in pharmacology 2017; 8:247. http://www.ncbi.nlm.nih.gov/pubmed/?term=28529486
  15. Ovrakh T, Serik S, Kochubiei O. Impact of atorvastatin and rosuvastatin on residual on-clopidogrel treatment platelet reactivity in patients with ischemic heart disease and type 2 diabetes mellitus after acute coronary syndrome. Georgian medical news 2017:7-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=28574378 (Article in Russian)
  16. Umeh G, Huffman MD. Challenges and opportunities in accessing trial data: an example from statin primary prevention trials. Heart Asia 2017; 9:99-101. http://www.ncbi.nlm.nih.gov/pubmed/?term=28469714
  17. Fauchier L, Clementy N, Pierre B, Babuty D. Statin and Atrial Fibrilation: When does it work? Journal of atrial fibrillation 2012; 5:443. http://www.ncbi.nlm.nih.gov/pubmed/?term=28496754
  18. Phillips KP. Role of Inflammation in Initiation and Perpetuation of Atrial Fibrillation: A Systematic Review of the Published Data. Journal of atrial fibrillation 2013; 6:935. http://www.ncbi.nlm.nih.gov/pubmed/?term=28496901
  19. Finsterer J, Frank M. Management of statin myopathy. Journal of cachexia, sarcopenia and muscle 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28466578
  20. Bril F, Portillo Sanchez P, Lomonaco R et al. Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post-hoc Analysis of a Randomized Trial. J Clin Endocrinol Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28575232
  21. Orringer CE, Jacobson TA, Saseen JJ et al. Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28532784
  22. Lu VM, McDonald KL. The current evidence of statin use affecting glioblastoma prognosis. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28495423
  23. Cassidy-Vu L, Joe E, Kirk JK. Role of Statin Drugs for Polycystic Ovary Syndrome. Journal of family & reproductive health 2016; 10:165-175. http://www.ncbi.nlm.nih.gov/pubmed/?term=28546815
  24. Sugiyama Y, Kazuya M, Toshimoto K. Is ethnic variability in the exposure to rosuvastatin explained only by genetic polymorphisms in OATP1B1 and BCRP or should the contribution of intrinsic ethnic differences in OATP1B1 be considered? Journal of pharmaceutical sciences 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28479351
  25. Takata K, Psaltis PJ, Nicholls SJ. Investigating the long-term legacy of statin therapy. J Thorac Dis 2017; 9:936-939. http://www.ncbi.nlm.nih.gov/pubmed/?term=28523141
  26. Ratchford EV. Medical management of claudication. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28533077
  27. Curfman G. Risks of Statin Therapy in Older Adults. JAMA Intern Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28531249
  28. Freedman DM, Pfeiffer RM. Ascertainment Bias in Statin Use and Alzheimer Disease Incidence. JAMA neurology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28459949
  29. Son WD, Teng CL. Do statins adversely affect the HbA1c of diabetic patients? Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia 2017; 12:39-40. http://www.ncbi.nlm.nih.gov/pubmed/?term=28503276
  30. Athyros VG, Alexandrides TK, Bilianou H et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017; 71:17-32. http://www.ncbi.nlm.nih.gov/pubmed/?term=28521870
  31. Caliceti C, Rizzo P, Ferrari R et al. Novel role of the nutraceutical bioactive compound berberine in lectin-like OxLDL receptor 1-mediated endothelial dysfunction in comparison to lovastatin. Nutrition, metabolism, and cardiovascular diseases : NMCD 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28511903
  32. Aday AW, Beckman JA. Medical Management of Asymptomatic Carotid Artery Stenosis. Prog Cardiovasc Dis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28539213

Safety and side effects

  1. Reith C, Staplin N, Herrington WG et al. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrol 2017; 18:147. http://www.ncbi.nlm.nih.gov/pubmed/?term=28460629
  2. Hawkes N. Patients told about muscle pain are more likely to report it, statin study finds. Bmj 2017; 357:j2144. http://www.ncbi.nlm.nih.gov/pubmed/?term=28468751
  3. Rosenson RS, Gandra SR, McKendrick J et al. Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries. Cardiovasc Drugs Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28466399
  4. Ehelepola NDB, Sathkumara S, Bandara H, Kalupahana KLR. Atorvastatin-Diltiazem Combination Induced Rhabdomyolysis Leading to Diagnosis of Hypothyroidism. Case reports in medicine 2017; 2017:8383251. http://www.ncbi.nlm.nih.gov/pubmed/?term=28487744
  5. Michiels S, Dierickx D, Taelman V et al. One biopsy, two diagnoses: statin-induced autoimmune myopathy in combination with extranodal marginal zone lymphoma. Clinical and experimental rheumatology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28516888
  6. Sweidan AJ, Leung A, Kaiser CJ et al. A Case of Statin-Associated Autoimmune Myopathy. Clinical medicine insights. Case reports 2017; 10:1179547616688231. http://www.ncbi.nlm.nih.gov/pubmed/?term=28469499
  7. Kitzmiller JP, Luzum JA, Dauki A et al. Candidate-Gene Study of Functional Polymorphisms in SLCO1B1 and CYP3A4/5 and the Cholesterol-Lowering Response to Simvastatin. Clinical and translational science 2017; 10:172-177. http://www.ncbi.nlm.nih.gov/pubmed/?term=28482130
  8. Kim TE, Ha N, Kim Y et al. Effect of epigallocatechin-3-gallate, major ingredient of green tea, on the pharmacokinetics of rosuvastatin in healthy volunteers. Drug design, development and therapy 2017; 11:1409-1416. http://www.ncbi.nlm.nih.gov/pubmed/?term=28533679
  9. Thakkar D, Dash RP. Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Observations and introspection of the bioanalysis. Drug design, development and therapy 2017; 11:1263-1265. http://www.ncbi.nlm.nih.gov/pubmed/?term=28461740
  10. Sbrana F, Dal Pino B, Bigazzi F et al. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else? Eur J Prev Cardiol 2017:2047487317712419. http://www.ncbi.nlm.nih.gov/pubmed/?term=28555526
  11. Toth S, Sajty M, Pekarova T et al. Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia. Journal of basic and clinical physiology and pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28541926
  12. Finsterer J, Frank M. Management of statin myopathy. Journal of cachexia, sarcopenia and muscle 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28466578
  13. Kareem H, Sahu D, Rao MS, Devasia T. Statin Induced Rhabdomyolysis with Non Oliguric Renal Failure: A Rare Presentation. J Clin Diagn Res 2017; 11:Fd01-fd02. http://www.ncbi.nlm.nih.gov/pubmed/?term=28511404
  14. Bril F, Portillo Sanchez P, Lomonaco R et al. Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post-hoc Analysis of a Randomized Trial. J Clin Endocrinol Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28575232
  15. Offman E, Davidson M, Nilsson C. Assessment of pharmacokinetic interaction between omega-3 carboxylic acids and the statins rosuvastatin and simvastatin: Results of 2 phase I studies in healthy volunteers. J Clin Lipidol 2017; 11:739-748. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506390
  16. Huang F, Marzin K, Koenen R et al. Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover Study. Journal of clinical pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28513969
  17. Beale DJ. Mislabeling of Study Design and Overstatement of Findings in "Rechallenging Statin Therapy in Veterans With Statin-Induced Myopathy Post Vitamin D Replenishment". Journal of pharmacy practice 2017; 30:385. http://www.ncbi.nlm.nih.gov/pubmed/?term=28511632
  18. Benet LZ, Wu HF. Understanding the Potential Interethnic Difference in Rosuvastatin Pharmacokinetics. Journal of pharmaceutical sciences 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28502797
  19. Sugiyama Y, Kazuya M, Toshimoto K. Is ethnic variability in the exposure to rosuvastatin explained only by genetic polymorphisms in OATP1B1 and BCRP or should the contribution of intrinsic ethnic differences in OATP1B1 be considered? Journal of pharmaceutical sciences 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28479351
  20. Yamashita S, Hasegawa T, Tachihara M et al. Quantitative Analysis of the Transporter Mediated drug-drug Interaction Between Atorvastatin and Rifampicin using a Stable Isotope-IV Method. Journal of pharmaceutical sciences 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28457720
  21. Sato T, Mishima E, Mano N et al. Potential drug interactions mediated by renal organic anion transporter OATP4C1. J Pharmacol Exp Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28550055
  22. Deska P, Nowicki M. Short-term changes of serum potassium concentration induced by physical exercise in patient with arterial hypertension treated with angiotensin-converting enzyme inhibitor alone or in combination with statin. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 2017; 68:133-138. http://www.ncbi.nlm.nih.gov/pubmed/?term=28456777
  23. Heydari B, Khalili H, Beigmohammadi MT et al. Effects of atorvastatin on biomarkers of acute kidney injury in amikacin recipients: A pilot, randomized, placebo-controlled, clinical trial. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 2017; 22:39. http://www.ncbi.nlm.nih.gov/pubmed/?term=28465698
  24. Curfman G. Risks of Statin Therapy in Older Adults. JAMA Intern Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28531249
  25. Gupta A, Thompson D, Whitehouse A et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28476288
  26. Pedro-Botet J, Rubies-Prat J. Statin-associated muscle symptoms: beware of the nocebo effect. Lancet 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28476289
  27. Son WD, Teng CL. Do statins adversely affect the HbA1c of diabetic patients? Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia 2017; 12:39-40. http://www.ncbi.nlm.nih.gov/pubmed/?term=28503276
  28. Study could curb exaggerated claims of statin side effects. Nursing standard (Royal College of Nursing (Great Britain) : 1987) 2017; 31:16. http://www.ncbi.nlm.nih.gov/pubmed/?term=28537191
  29. Licarete E, Sesarman A, Rauca VF et al. HIF-1alpha acts as a molecular target for simvastatin cytotoxicity in B16.F10 melanoma cells cultured under chemically induced hypoxia. Oncology letters 2017; 13:3942-3950. http://www.ncbi.nlm.nih.gov/pubmed/?term=28521491
  30. Kim TM, Kim H, Jeong YJ et al. The differences in the incidence of diabetes mellitus and prediabetes according to the type of HMG-CoA reductase inhibitors prescribed in Korean patients. Pharmacoepidemiol Drug Saf 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28556206

Stroke and CNS

  1. Smith KB, Kang P, Sabbagh MN. The Effect of Statins on Rate of Cognitive Decline in Mild Cognitive Impairment. Alzheimer's & dementia (New York, N. Y.) 2017; 3:149-156. http://www.ncbi.nlm.nih.gov/pubmed/?term=28480324
  2. Kumagai N, Nusser JA, Inoue H et al. Effect of Addition of a Statin to Warfarin on Thromboembolic Events in Japanese Patients With Nonvalvular Atrial Fibrillation and Diabetes Mellitus. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28532776
  3. Knight RA, Nagaraja TN, Li L et al. A Prospective Safety Trial of Atorvastatin Treatment to Assess Rebleeding after Spontaneous Intracerebral Hemorrhage: A Serial MRI Investigation. Austin journal of cerebrovascular disease & stroke 2016; 3. http://www.ncbi.nlm.nih.gov/pubmed/?term=28529979
  4. Huang W, Li Z, Zhao L, Zhao W. Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer's disease via modulating the expression of miR-106b. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017; 92:46-57. http://www.ncbi.nlm.nih.gov/pubmed/?term=28528185
  5. Chung CM, Lin MS, Hsu JT et al. Effects of statin therapy on cerebrovascular and renal outcomes in patients with predialysis advanced chronic kidney disease and dyslipidemia. J Clin Lipidol 2017; 11:422-431.e422. http://www.ncbi.nlm.nih.gov/pubmed/?term=28502499
  6. Sarfo FS, Ovbiagele B. Stroke minimization through additive anti-atherosclerotic agents in routine treatment (SMAART): A pilot trial concept for improving stroke outcomes in sub-Saharan Africa. J Neurol Sci 2017; 377:167-173. http://www.ncbi.nlm.nih.gov/pubmed/?term=28477689
  7. Freedman DM, Pfeiffer RM. Ascertainment Bias in Statin Use and Alzheimer Disease Incidence. JAMA neurology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28459949
  8. Fang SC, Xie H, Chen F et al. Simvastatin ameliorates memory impairment and neurotoxicity in streptozotocin-induced diabetic mice. Neuroscience 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28499972
  9. Aday AW, Beckman JA. Medical Management of Asymptomatic Carotid Artery Stenosis. Prog Cardiovasc Dis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28539213
  10. Wang H, Zhou J, Liu QZ et al. Simvastatin and Bezafibrate ameliorate Emotional disorder Induced by High fat diet in C57BL/6 mice. Scientific reports 2017; 7:2335. http://www.ncbi.nlm.nih.gov/pubmed/?term=28539670
Triglycerides/HDL
  1. Ferrari R, Aguiar C, Alegria E et al. Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. European heart journal supplements : journal of the European Society of Cardiology 2016; 18:C2-c12. http://www.ncbi.nlm.nih.gov/pubmed/?term=28533705
  2. Lin H, Zhang YM. The effect of Ezetimibe and Simvastatin Combination Therapy on percutaneous coronary intervention patients. Int J Cardiol 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28550977
  3. Ling Y, Jiang J, Wu B, Gao X. Serum triglyceride, high-density lipoprotein cholesterol, apolipoprotein B, and coronary heart disease in a Chinese population undergoing coronary angiography. J Clin Lipidol 2017; 11:646-656. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506386
  4. Quinn AG, Schwemberger R, Stock EO et al. Moderate statin treatment reduces prebeta-1 high-density lipoprotein levels in dyslipidemic patients. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28558949

Trials

  1. Iraji F, Banihashemi SH, Faghihi G et al. A Comparison of Betamethasone Valerate 0.1% Cream Twice Daily Plus Oral Simvastatin Versus Betamethasone Valerate 0.1% Cream Alone in the Treatment of Vitiligo Patients. Advanced biomedical research 2017; 6:34. http://www.ncbi.nlm.nih.gov/pubmed/?term=28516068
  2. Smith KB, Kang P, Sabbagh MN. The Effect of Statins on Rate of Cognitive Decline in Mild Cognitive Impairment. Alzheimer's & dementia (New York, N. Y.) 2017; 3:149-156. http://www.ncbi.nlm.nih.gov/pubmed/?term=28480324
  3. Landray MJ, Reveal Collaborative G. Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. Am Heart J 2017; 187:182-190. http://www.ncbi.nlm.nih.gov/pubmed/?term=28454801
  4. Tan JT, Barry AR. Coenzyme Q10 supplementation in the management of statin-associated myalgia. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2017; 74:786-793. http://www.ncbi.nlm.nih.gov/pubmed/?term=28546301
  5. Teramoto T, Daida H, Ikewaki K et al. Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia. Atherosclerosis 2017; 261:69-77. http://www.ncbi.nlm.nih.gov/pubmed/?term=28478132
  6. Knight RA, Nagaraja TN, Li L et al. A Prospective Safety Trial of Atorvastatin Treatment to Assess Rebleeding after Spontaneous Intracerebral Hemorrhage: A Serial MRI Investigation. Austin journal of cerebrovascular disease & stroke 2016; 3. http://www.ncbi.nlm.nih.gov/pubmed/?term=28529979
  7. Reith C, Staplin N, Herrington WG et al. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrol 2017; 18:147. http://www.ncbi.nlm.nih.gov/pubmed/?term=28460629
  8. Auscher S, Logstrup BB, Moller JE et al. Effects of Intensive Statin Therapy on Left Ventricular Function in Patients with Myocardial Infarction and Abnormal Glucose Tolerance. Cardiology 2017; 138:16-25. http://www.ncbi.nlm.nih.gov/pubmed/?term=28514784
  9. Muller-Wieland D, Leiter LA, Cariou B et al. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. Cardiovascular diabetology 2017; 16:70. http://www.ncbi.nlm.nih.gov/pubmed/?term=28545518
  10. Rosenson RS, Gandra SR, McKendrick J et al. Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries. Cardiovasc Drugs Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28466399
  11. Bedi P, Chalmers JD, Graham C et al. A randomised control trial of atorvastatin in bronchiectasis patients infected with Pseudomonas aeruginosa- a proof of concept study. Chest 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28554732
  12. Pokharel Y, Chinnakondepalli K, Vilain K et al. Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circ Cardiovasc Qual Outcomes 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506979
  13. Yokote K, Kanada S, Matsuoka O et al. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive- Results From a Randomized, Placebo-Controlled, Dose-Ranging Study. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28539539
  14. Ports WC, Fayyad R, DeMicco DA et al. Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis. Clinical drug investigation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28573499
  15. Blackwood DP, LaVallee RK, Al Busaidi A et al. A randomized trial of the effects of ezetimibe on the absorption of omega-3 fatty acids in cardiac disease patients: A pilot study. Clinical nutrition ESPEN 2015; 10:e155-e159. http://www.ncbi.nlm.nih.gov/pubmed/?term=28531469
  16. Agus A, Hulme C, Verghis RM et al. Simvastatin for patients with acute respiratory distress syndrome: long-term outcomes and cost-effectiveness from a randomised controlled trial. Crit Care 2017; 21:108. http://www.ncbi.nlm.nih.gov/pubmed/?term=28511660
  17. Brosnahan G, Abebe KZ, Rahbari-Oskoui FF et al. Effect of statin therapy on the progression of autosomal dominant polycystic kidney disease. A secondary analysis of the HALT PKD trials. Current hypertension reviews 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28460625
  18. Hennig M, Brandt A, Bautembach-Minkowska J et al. When do paediatric patients with familial hypercholesterolemia need statin therapy? Developmental period medicine 2017; 21:43-50. http://www.ncbi.nlm.nih.gov/pubmed/?term=28551692
  19. Kim TE, Ha N, Kim Y et al. Effect of epigallocatechin-3-gallate, major ingredient of green tea, on the pharmacokinetics of rosuvastatin in healthy volunteers. Drug design, development and therapy 2017; 11:1409-1416. http://www.ncbi.nlm.nih.gov/pubmed/?term=28533679
  20. Morelli VM, Lijfering WM, Bos MHA et al. Lipid levels and risk of venous thrombosis: results from the MEGA-study. European journal of epidemiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28540474
  21. Cioboata R, Gaman A, Trasca D et al. Pharmacological management of non-alcoholic fatty liver disease: Atorvastatin versus pentoxifylline. Experimental and therapeutic medicine 2017; 13:2375-2381. http://www.ncbi.nlm.nih.gov/pubmed/?term=28565851
  22. Ovrakh T, Serik S, Kochubiei O. [IMPACT OF ATORVASTATIN AND ROSUVASTATIN ON RESIDUAL ON-CLOPIDOGREL TREATMENT PLATELET REACTIVITY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND TYPE 2 DIABETES MELLITUS AFTER ACUTE CORONARY SYNDROME]. Georgian medical news 2017:7-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=28574378
  23. Chua SHH, Tioleco GMS, Dayrit CAF et al. Atorvastatin as adjunctive therapy for chronic plaque type psoriasis versus betamethasone valerate alone: A randomized, double-blind, placebo-controlled trial. Indian journal of dermatology, venereology and leprology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28540870
  24. Lin H, Zhang YM. The effect of Ezetimibe and Simvastatin Combination Therapy on percutaneous coronary intervention patients. Int J Cardiol 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28550977
  25. Xing L, Higuma T, Wang Z et al. Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography: A 4-Year Follow-Up Study. J Am Coll Cardiol 2017; 69:2502-2513. http://www.ncbi.nlm.nih.gov/pubmed/?term=28521888
  26. Stanifer JW, Charytan DM, White J et al. Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. Journal of the American Society of Nephrology : JASN 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28507057
  27. Quinn AG, Schwemberger R, Stock EO et al. Moderate statin treatment reduces prebeta-1 high-density lipoprotein levels in dyslipidemic patients. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28558949
  28. Silvennoinen R, Turunen JH, Kovanen PT et al. Attitudes and actions: A survey to assess statin use among Finnish patients with increased risk for cardiovascular events. J Clin Lipidol 2017; 11:485-494. http://www.ncbi.nlm.nih.gov/pubmed/?term=28502506
  29. Wu CK, Yeh CF, Chiang JY et al. Effects of atorvastatin treatment on left ventricular diastolic function in peritoneal dialysis patients-The ALEVENT clinical trial. J Clin Lipidol 2017; 11:657-666. http://www.ncbi.nlm.nih.gov/pubmed/?term=28506387
  30. Ohta A, Kato H, Ishii S et al. Effect of Ezetimibe Monotherapy on Low-Density Lipoprotein Cholesterol and on Markers of Cholesterol Synthesis and Absorption in Japanese Patients With Hypercholesterolemia. Journal of clinical medicine research 2017; 9:476-481. http://www.ncbi.nlm.nih.gov/pubmed/?term=28496547
  31. Raphael J, Collins SR, Wang XQ et al. Perioperative statin use is associated with decreased incidence of primary graft dysfunction after lung transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28552627
  32. Tjia J, Kutner JS, Ritchie CS et al. Perceptions of Statin Discontinuation among Patients with Life-Limiting Illness. Journal of palliative medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28520522
  33. Deska P, Nowicki M. Short-term changes of serum potassium concentration induced by physical exercise in patient with arterial hypertension treated with angiotensin-converting enzyme inhibitor alone or in combination with statin. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 2017; 68:133-138. http://www.ncbi.nlm.nih.gov/pubmed/?term=28456777
  34. Han BH, Sutin D, Williamson JD et al. Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial. JAMA Intern Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28531241
  35. Japaridze L, Sadunishvili M. The short term effect of atorvastatin plus ezetimibe therapy vs. atorvastatin monotherapy on clinical outcome in the acute coronary syndrome patients by gender. Kardiol Pol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28553847
  36. Gupta A, Thompson D, Whitehouse A et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28476288
  37. Pedro-Botet J, Rubies-Prat J. Statin-associated muscle symptoms: beware of the nocebo effect. Lancet 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28476289
  38. Wang P, Yang J, Yang Y, Ding Z. Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Pak J Med Sci 2017; 33:260-264. http://www.ncbi.nlm.nih.gov/pubmed/?term=28523018
  39. Nobre MRC, Domingues RZL. Patient adherence to ischemic heart disease treatment. Rev Assoc Med Bras (1992) 2017; 63:252-260. http://www.ncbi.nlm.nih.gov/pubmed/?term=28489132
  40. Chen M, Lu J, Chen Q et al. [Statin in the treatment of ALI/ARDS: a systematic review and Meta-analysis based on international databases]. Zhonghua wei zhong bing ji jiu yi xue 2017; 29:51-56. http://www.ncbi.nlm.nih.gov/pubmed/?term=28459404

Women and elderly

  1. Raparelli V, Pannitteri G, Todisco T et al. Treatment and Response to Statins: Gender-related Differences. Curr Med Chem 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28552051
  2. Toth S, Sajty M, Pekarova T et al. Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia. Journal of basic and clinical physiology and pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28541926
  3. Curfman G. Risks of Statin Therapy in Older Adults. JAMA Intern Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28531249


 
 
 


Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.

Cancella iscrizione | Unsubscribe | Inviato con MailUp